Richard Pzena's HALO Position Overview
Richard Pzena (via Pzena Investment Management LLC) currently holds 4,107 shares of Halozyme Therapeutics, Inc. (HALO) worth $301,207, representing 0.00% of the portfolio. First purchased in 2022-Q1, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Richard Pzena has maintained a strategic position in HALO, demonstrating sustained confidence in this investment. Largest reduction occurred in Q1 2023, reducing 5,291 shares.
Analysis based on 13F filings available since 2013 Q2
Richard Pzena's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Richard Pzena
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2022 | +15,738 | New Buy | 15,738 | $39.90 |
| Q2 2022 | -15,738 | Sold Out | 15,738 | $0.00 |
| Q4 2022 | +14,507 | New Buy | 14,507 | $56.90 |
| Q1 2023 | -5,291 | Reduce 36.47% | 9,216 | $38.19 |
| Q2 2023 | -9,216 | Sold Out | 9,216 | $0.00 |
| Q3 2025 | +4,107 | New Buy | 4,107 | $73.34 |
Richard Pzena's Halozyme Therapeutics Investment FAQs
Richard Pzena first purchased Halozyme Therapeutics, Inc. (HALO) in Q1 2022, acquiring 15,738 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Richard Pzena has held Halozyme Therapeutics, Inc. (HALO) for 15 quarters since Q1 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Richard Pzena's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q1 2022, adding 15,738 shares worth $628,000. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Richard Pzena's firm, Pzena Investment Management LLC, owns 4,107 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $301,207. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.00% of Richard Pzena's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Richard Pzena's peak holding in Halozyme Therapeutics, Inc. (HALO) was 15,738 shares, as reported at the end of Q1 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.